.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,252,839

« Back to Dashboard
Patent 7,252,839 protects KYLEENA and SKYLA and is included in two NDAs.

This patent has thirty patent family members in twenty-six countries.

Summary for Patent: 7,252,839

Title:Delivery system and a manufacturing process of a delivery system
Abstract: A delivery system including a body construction (7) and at least one capsule (8) containing a pharmaceutical composition, the capsule having at least a first end and a second end. The body construction (7, 12, 34) has at least two locking parts (9, 10), each locking part (9, 10) having at least a first end and a second end, the first end of each locking part (9, 10) having a surface adapted to face and cover one of the at least first and second ends of the capsule (8). The diameter of at least one of the locking parts varies along its length between the first end and the second end, and the capsule (8) is mounted between the at least two locking parts. Also disclosed is a manufacturing process of a delivery system, the system including a body construction and at least one capsule containing a pharmaceutical composition.
Inventor(s): Hallinen; Esa (Lempaala{umlaut over ( )}, FI), Lyytikainen; Heikki (Naantali, FI), Jarvela; Pentti (Lahti, FI), Kivi; Ilkka (Pirkkala, FI)
Assignee: Schering Oy (Turku, FI)
Application Number:10/528,237
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 12th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
KYLEENA
levonorgestrel
INTRAUTERINE DEVICE;INTRAUTERINE208224-001Sep 16, 2016RXYes7,252,839► subscribeY
Bayer Hlthcare
SKYLA
levonorgestrel
INTRAUTERINE DEVICE;INTRAUTERINE203159-001Jan 9, 2013RXYes7,252,839► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,252,839

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02020869Sep 18, 2002
PCT Information
PCT FiledSeptember 04, 2003PCT Application Number:PCT/FI03/00647
PCT Publication Date:April 01, 2004PCT Publication Number: WO2004/026196

International Patent Family for Patent: 7,252,839

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2297810► subscribe
Russian Federation2005111234► subscribe
Portugal1539063► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc